BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress

  October 7, 2025

   · 

  5 min read
• Press Releases

  RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older

  October 7, 2025

   · 

  5 min read
• Press Releases

  Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer

  October 7, 2025

   · 

  3 min read
• Press Releases

  Blue Earth Therapeutics Presents Modelling Data Supporting Early Dose Intensification of Lutetium (177Lu) rhPSMA-10.1 Injection in mCRPC

  October 7, 2025

   · 

  5 min read
• Press Releases

  Salipro Biotech Strengthens Global IP Portfolio with Two New Japanese Patents

  October 7, 2025

   · 

  2 min read
• Press Releases

  New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress

  October 7, 2025

   · 

  3 min read
• Press Releases

  Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings

  October 7, 2025

   · 

  3 min read
• 

  Obesity

  Skye’s CB1 Inhibitor Shows ‘Intriguing Synergy’ With Wegovy, Despite Mid-Stage Obesity Fail

  Skye Bioscience’s nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when combined with Wegovy, according to analysts at William Blair.

  October 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug pricing

  Amgen Hops on DTC Train To Offer Repatha at 60% Discount

  Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction from the current wholesale acquisition cost of $527.70.

  October 7, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Pfizer Beat Out Two Other Metsera Suitors for Takeover

  Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New York pharma, however, offered the smoothest transaction with the greatest likelihood of success.

  October 7, 2025

   · 

  3 min read

   · 

  Tristan Manalac